The data shows the top 20 brands for respiratory diseases based on revenue in the U.S. in 2016. In that year, Merck's Dulera generated some 412 million USD in revenues. Thus, Dulera was ranked 15th among respiratory products in the U.S.
Top respiratory products
Spiriva from Boehringer Ingelheim and Symbicort Turbohaler from AstraZeneca are among the top respiratory brands in the U.S., generating 1.87 billion and 1.24 billion USD in 2016. The U.S. accounted for around half of the world’s pharmaceutical top product revenues.
